Hepatitis C dsRNA Effector Molecules Targeting Conserved Regions
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Hepatitis C Virus (HCV) infection, particularly those using pegylated interferon and ribavirin, have limited efficacy, especially for genotype 1 patients, and are associated with significant side effects, necessitating the development of more effective and tolerable treatment options that can inhibit HCV replication and prevent drug-resistant escape mutants.
Innovation Solution
The use of double-stranded RNA (dsRNA) effector molecules specifically designed to target conserved regions of the HCV genome, such as HCV Conserved Region 1, 2, and 5, and active target regions, to silence HCV RNA and inhibit viral replication, potentially administered concomitantly to delay the emergence of drug-resistant mutants, utilizing constructs that encode these dsRNA molecules under the control of RNA polymerase promoters for expression in mammalian cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pegylated interferon and ribavirin are used to treat HCV infection, then viral replication is inhibited, but treatment efficacy is limited and side effects are significant
Solution Approach 1:
The invention changes the therapeutic parameter from conventional interferon/ribavirin combination to RNA interference-based dsRNA molecules, fundamentally altering the mechanism of action to achieve better efficacy with improved tolerability
Solution Approach 2:
The invention replaces the immunomodulatory mechanism of interferon with a direct sequence-specific RNA silencing mechanism, substituting a complex immune response system with a more precise molecular targeting approach
2Reliability
If single dsRNA effector molecules are used to target HCV, then viral replication is inhibited, but drug-resistant escape mutants emerge
Solution Approach 1:
The invention divides the antiviral strategy into multiple parallel dsRNA effector molecules, each targeting different conserved regions of the HCV genome, thereby preventing any single viral mutation from conferring resistance
Solution Approach 2:
The invention creates a composite therapeutic approach by combining multiple dsRNA effector molecules with different target specificities, forming a multi-target regimen that addresses viral variability and prevents escape mutant emergence
3Adaptability or versatility
If RNAi-based therapeutics are designed to target conserved HCV regions, then broad genotype coverage is achieved, but target regions are highly structured and inaccessible
Solution Approach 1:
The invention identifies and targets specific local regions within the HCV genome that possess both high conservation across genotypes and relative accessibility to RNAi mechanisms, optimizing the balance between broad coverage and target accessibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces HCV replication and antigen expression in mammalian cells, potentially improving treatment response rates and reducing the emergence of drug-resistant viral strains, while offering a more tolerable side effect profile compared to existing therapies.
Implementation Method 1
RNA interference is a sequence-specific effect, therapeutic or prophylactic RNAi molecules must be specific for HCV target sequences
Implementation Method 2
The dsRNA effector molecule comprises: (1) a sequence of at least 19 consecutive nucleotides having at least 90% identity with a nucleotide sequence within HCV Conserved Region 1, HCV Conserved Region 2, or HCV Conserved Region 5; and (2) its complementary sequence
Data Source
AI summary
The present invention provides agents, compositions, constructs and methods for silencing HCV polynucleotides, as well as methods and compositions for treating or preventing HCV infection in a mammalian cell. In one aspect, the present invention provides an agent or composition comprising at least one double-stranded RNA effector molecule or complex. The double-stranded RNA effector molecule or complex comprises: (1) a sequence of at least 19 nucleotides having at least 90% identity with a nucleotide sequence within HCV Conserved Region 1 (SEQ ID NO: 2), HCV Conserved Region 2 (SEQ ID NO: 3), HCV Conserved Region 5 (SEQ ID NO: 4), (ATR)-1 (SEQ ID NO: 86), ATR-2 (SEQ ID NO: 87), ATR-3 (SEQ ID NO: 88), ATR-4 (SEQ ID NO: 89); and (2) its complementary sequence. In another aspect, the present invention provides a construct suitable for replication in a host cell, and/or suitable for expression of an RNA molecule or complex of the invention in vitro or in vivo. In a third aspect, the present invention provides a method for silencing HCV RNA in a mammalian cell, which comprises administering to the mammalian cell an agent, composition, or construct of the invention in a manner and amount effective to silence HCV RNA in the cell. In a related aspect, the invention provides a method for treating or preventing HCV infection in a patient, comprising administering to the patient an effective amount of an agent, composition, or construct of the invention as described herein.